Evidence map›Paper›PMID 33216031›Full record

ArticleJournal of Alzheimer's disease : JAD2021

Use of Direct-Acting Antiviral Agents and Survival Among Medicare Beneficiaries with Dementia and Chronic Hepatitis C.

Linh Tran, Jeah Jung, Caroline Carlin, Sunmin Lee, Chen Zhao, Roger Feldman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Linh TranDepartment of Health Policy and Administration, College of Health and Human Development, Pennsylvania, State University, University Park, PA, USA.
Jeah JungDepartment of Health Policy and Administration, College of Health and Human Development, Pennsylvania, State University, University Park, PA, USA.
Caroline CarlinDepartment of Family Medicine and Community Health, School of Medicine, University of Minnesota, Minneapolis, MN, USA.
Sunmin LeeDepartment of Epidemiology, School of Medicine, University of California, Irvine, Irvine, CA, USA.
Chen ZhaoDepartment of Neurology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Roger FeldmanDivision of Health Policy and Management, School of Public Health, University of Minnesota, MN, USA.
Pennsylvania State University · USMinnesota Department of Health · USPenn State Milton S. Hershey Medical Center · USUniversity of California, Irvine · USUniversity of Minnesota · US

Funding

Use of New Hepatitis C Drugs and Patients' Health Outcomes in MedicareR01AG055636 · NIA · PENNSYLVANIA STATE UNIVERSITY, THE · PI JUNG, JEAH · 2018 to 2020
$1.5M
NIA NIH HHS R01 AG055636
6 · The paper itself

Abstract

backgroundMany patients with Alzheimer's disease and related dementia (ADRD) have chronic hepatitis C due to the high prevalence of both conditions among elderly populations. Direct-acting antivirals (DAAs) are effective in treating hepatitis C virus (HCV). However, the complexity of ADRD care may affect DAA use and outcomes among patients with HCV and ADRD. Little information exists on uptake of DAAs, factors associated with DAA use, and health benefits of DAAs among patients with HCV and ADRD.

objectiveTo examine use and survival benefits of DAAs in Medicare patients with HCV and ADRD.

methodsThe study included Medicare patients with HCV between 2014 and 2017. We estimated Cox proportional hazards regressions to examine the association between having ADRD and DAA use, and the relation between DAA use and survival among patients with HCV and ADRD.

resultsThe adjusted hazard of initiating a DAA was 50% lower in patients with ADRD than those without ADRD (adjusted HR = 0.50, 95% CI: 0.46-0.54). The hazard of DAA use among ADRD patients with behavioral disturbances was 68% lower than non-ADRD patients (adjusted HR = 0.32, 95% CI: 0.28-0.37). DAA treatment was associated with a significant reduction in mortality among ADRD patients (adjusted HR = 0.52, 95% CI: 0.44-0.61).

conclusionThe rate of DAA treatment in patients with HCV and ADRD was low, particularly among those with behavioral disturbance. The survival benefits of DAA treatment for patients with ADRD were substantial.

Indexed as

MortalityAgedAlzheimer DiseaseAntiviral AgentsComorbidityDementiaFemaleHepatitis C, ChronicHumansKaplan-Meier EstimateMaleMedicareMiddle AgedPractice Patterns, Physicians'Problem BehaviorProportional Hazards ModelsAntiviral AgentsAlzheimer’s diseasecomorbiditydementiadirect-acting antiviralshepatitis C

Identifiers

PMID33216031
PMCPMC7855832
OpenAlexW3101491548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.